Hematologic Changes in Sepsis and Their Therapeutic Implications

 

 Buy Article Permissions and Reprints

ABSTRACT

The blood and bone marrow constitute the hematologic organ system. Unlike other organ systems, hematologic organs are distributed in space and provide for a variety of seemingly unrelated functions. The hematologic system has both cellular and fluid-phase elements. Cellular elements include erythrocytes, leukocytes, and platelets; fluid phase elements include coagulation factors, natural antithrombotics, and proteins of the fibrinolytic system. The most common abnormalities of the hematologic system in patients with sepsis are anemia, leukocytosis, thrombocytopenia, and activation of the hemostatic system. Dysfunction of the hematologic organ system is an early manifestation of severe sepsis and is seen in virtually all patients with this disease. In concert with alterations in the endothelium, hematologic changes reflect both the body's reaction to an infectious insult as well as attempts to restore homeostasis. Dysfunction of the hematologic organ system can contribute to multiple organ dysfunctions and death. Recognizing these sepsis-associated changes and understanding the underlying pathophysiology are key to improving outcomes in patients with this deadly disease.

REFERENCES

• 1 Angus D C, Linde-Zwirble W T, Lidicker J, Clermont G, Carcillo J, Pinsky M R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.  Crit Care Med. 2001;  29 1303-1310
  CrossrefPubMedGoogle Scholar
• 2 Aird W C. The hematologic system as a marker of organ dysfunction in sepsis.  Mayo Clin Proc. 2003;  78 869-881
  PubMedGoogle Scholar
• 3 Sporn L, Huber P. Endothelial cell biology. In Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN Hemostasis and Thrombosis Philadelphia: Lippincott; Williams & Wilkins 2001
  Google Scholar
• 4 Hack C E, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation.  Crit Care Med. 2001;  29(7 Suppl) S21-S27
  PubMedGoogle Scholar
• 5 Esmon C T. The normal role of activated protein C in maintaining homeostasis and its relevance to critical illness.  Crit Care. 2001;  5 S7-12
  PubMedGoogle Scholar
• 6 Leclerc J, Pu Q, Corseaux D et al.. A single endotoxin injection in the rabbit causes prolonged blood vessel dysfunction and a procoagulant state.  Crit Care Med. 2000;  28 3672-3678
  PubMedGoogle Scholar
• 7 Vincent J L. Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology.  Crit Care. 2001;  5 S1-S5
  PubMedGoogle Scholar
• 8 Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis.  Crit Care Med. 2002;  30(5 Suppl) S302-S312
  PubMedGoogle Scholar
• 9 Krafte-Jacobs B, Brilli R. Increased circulating thrombomodulin in children with septic shock.  Crit Care Med. 1998;  26 933-938
  PubMedGoogle Scholar
• 10 Moss M, Gillespie M K, Ackerson L, Moore F A, Moore E E, Parsons P E. Endothelial cell activity varies in patients at risk for the adult respiratory distress syndrome.  Crit Care Med. 1996;  24 1782-1786
  PubMedGoogle Scholar
• 11 Hotchkiss R S, Karl I E. The pathophysiology and treatment of sepsis.  N Engl J Med. 2003;  348 138-150
  CrossrefPubMedGoogle Scholar
• 12 Baskurt O K, Gelmont D, Meiselman H J. Red blood cell deformability in sepsis.  Am J Respir Crit Care Med. 1998;  157 421-427
  PubMedGoogle Scholar
• 13 Langenfeld J E, Livingston D H, Machiedo G W. Red cell deformability is an early indicator of infection.  Surgery. 1991;  110 398-403 , discussion 403-404
  PubMedGoogle Scholar
• 14 Baskurt O K, Temiz A, Meiselman H J. Red blood cell aggregation in experimental sepsis.  J Lab Clin Med. 1997;  130 183-190
  CrossrefPubMedGoogle Scholar
• 15 van Iperen C E, Gaillard C A, Kraaijenhagen R J, Braam B G, Marx J J, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients.  Crit Care Med. 2000;  28 2773-2778
  PubMedGoogle Scholar
• 16 Zimmerman J E, Seneff M G, Sun X, Wagner D P, Knaus W A. Evaluating laboratory usage in the intensive care unit: patient and institutional characteristics that influence frequency of blood sampling.  Crit Care Med. 1997;  25 737-748
  PubMedGoogle Scholar
• 17 Vincent J L, Baron J F, Reinhart K et al.. Anemia and blood transfusion in critically ill patients.  JAMA. 2002;  288 1499-1507
  CrossrefPubMedGoogle Scholar
• 18 Smoller B R, Kruskall M S. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements.  N Engl J Med. 1986;  314 1233-1235
  CrossrefPubMedGoogle Scholar
• 19 Olivares M, Walter T, Osorio M, Chadud P, Schlesinger L. Anemia of a mild viral infection: the measles vaccine as a model.  Pediatrics. 1989;  84 851-855
  PubMedGoogle Scholar
• 20 Krantz S B. Pathogenesis and treatment of the anemia of chronic disease.  Am J Med Sci. 1994;  307 353-359
  PubMedGoogle Scholar
• 21 Andrews N C. Disorders of iron metabolism.  N Engl J Med. 1999;  341 1986-1995
  CrossrefPubMedGoogle Scholar
• 22 Shurin S B, Anderson P, Zollinger J, Rathbun R K. Pathophysiology of hemolysis in infections with Hemophilus influenzae type b.  J Clin Invest. 1986;  77 1340-1348
  PubMedGoogle Scholar
• 23 Su D, Roth R I, Levin J. Hemoglobin infusion augments the tumor necrosis factor response to bacterial endotoxin (lipopolysaccharide) in mice.  Crit Care Med. 1999;  27 771-778
  PubMedGoogle Scholar
• 24 Corwin H L, Parsonnet K C, Gettinger A. RBC transfusion in the ICU: is there a reason?.  Chest. 1995;  108 767-771
  CrossrefPubMedGoogle Scholar
• 25 Gazmuri R J, Shakeri S A. Blood transfusion and the risk of nosocomial infection: an underreported complication?.  Crit Care Med. 2002;  30 2389-2391
  CrossrefPubMedGoogle Scholar
• 26 Goodnough L T, Brecher M E, Kanter M H, AuBuchon J P. Transfusion medicine: first of two parts-blood transfusion.  N Engl J Med. 1999;  340 438-447
  CrossrefPubMedGoogle Scholar
• 27 Hébert P C, Wells G, Blajchman M A et al.. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.  N Engl J Med. 1999;  340 409-417
  CrossrefPubMedGoogle Scholar
• 28 Corwin H L, Gettinger A, Pearl R G et al.. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.  JAMA. 2002;  288 2827-2835
  CrossrefPubMedGoogle Scholar
• 29 Russell J A. Adding fuel to the fire: the supranormal oxygen delivery trials controversy.  Crit Care Med. 1998;  26 981-983
  PubMedGoogle Scholar
• 30 Rivers E, Nguyen B, Havstad S et al.. Early goal-directed therapy in the treatment of severe sepsis and septic shock.  N Engl J Med. 2001;  345 1368-1377
  CrossrefPubMedGoogle Scholar
• 31 Bone R C, Balk R A, Cerra F B et al.. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest 1992 101: 1644-1655
  Google Scholar
• 32 Medzhitov R, Janeway Jr C. Innate immunity.  N Engl J Med. 2000;  343 338-344
  CrossrefPubMedGoogle Scholar
• 33 Funke A, Berner R, Traichel B, Schmeisser D, Leititis J U, Niemeyer C M. Frequency, natural course, and outcome of neonatal neutropenia.  Pediatrics. 2000;  106(1 Pt 1) 45-51
  CrossrefPubMedGoogle Scholar
• 34 Root R K, Lodato R F, Patrick W et al.. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis.  Crit Care Med. 2003;  31 367-373
  CrossrefPubMedGoogle Scholar
• 35 Bernard G R, Vincent J L, Laterre P F et al.. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
  CrossrefPubMedGoogle Scholar
• 36 Warren B L, Eid A, Singer P et al.. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286 1869-1878
  CrossrefPubMedGoogle Scholar
• 37 Baughman R P, Lower E E, Flessa H C, Tollerud D J. Thrombocytopenia in the intensive care unit.  Chest. 1993;  104 1243-1247
  CrossrefPubMedGoogle Scholar
• 38 Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU.  Chest. 1999;  115 1363-1370
  CrossrefPubMedGoogle Scholar
• 39 Vanderschueren S, De Weerdt A, Malbrain M et al.. Thrombocytopenia and prognosis in intensive care.  Crit Care Med. 2000;  28 1871-1876
  CrossrefPubMedGoogle Scholar
• 40 Nijsten M W, ten Duis H J, Zijlstra J G, Porte R J, Zwaveling J H, Paling J C. The TH: blunted rise in platelet count in critically ill patients is associated with worse outcome.  Crit Care Med. 2000;  28 3843-3846
  CrossrefPubMedGoogle Scholar
• 41 Long M W. Thrombopoietin stimulation of hematopoietic stem/progenitor cells.  Curr Opin Hematol. 1999;  6 159-163
  CrossrefPubMedGoogle Scholar
• 42 Cramer E M. Megakaryocyte structure and function.  Curr Opin Hematol. 1999;  6 354-361
  CrossrefPubMedGoogle Scholar
• 43 Shibazaki M, Kawabata Y, Yokochi T, Nishida A, Takada H, Endo Y. Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides.  Infect Immun. 1999;  67 5186-5191
  PubMedGoogle Scholar
• 44 Tsujikawa A, Kiryu J, Yamashiro K et al.. Interactions between blood cells and retinal endothelium in endotoxic sepsis.  Hypertension. 2000;  36 250-258
  PubMedGoogle Scholar
• 45 Salat A, Murabito M, Boehm D et al.. Endotoxin enhances in vitro platelet aggregability in whole blood.  Thromb Res. 1999;  93 145-148
  CrossrefPubMedGoogle Scholar
• 46 Stephan F, Thioliere B, Verdy E, Tulliez M. Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock.  Clin Infect Dis. 1997;  25 1159-1164
  PubMedGoogle Scholar
• 47 Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor.  Am J Med. 1997;  103 114-120
  CrossrefPubMedGoogle Scholar
• 48 Stephan F, Cheffi M A, Kaplan C et al.. Autoantibodies against platelet glycoproteins in critically ill patients with thrombocytopenia.  Am J Med. 2000;  108 554-560
  CrossrefPubMedGoogle Scholar
• 49 Brieger D B, Mak K H, Kottke-Marchant K, Topol E J. Heparin-induced thrombocytopenia.  J Am Coll Cardiol. 1998;  31 1449-1459
  CrossrefPubMedGoogle Scholar
• 50 Warkentin T E, Hayward C P, Boshkov L K et al.. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.  Blood. 1994;  84 3691-3699
  CrossrefPubMedGoogle Scholar
• 51 Warkentin T E, Elavathil L J, Hayward C P, Johnston M A, Russett J I, Kelton J G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.  Ann Intern Med. 1997;  127 804-812
  CrossrefPubMedGoogle Scholar
• 52 Berkman N, Michaeli Y, Or R, Eldor A. EDTA-dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature.  Am J Hematol. 1991;  36 195-201
  PubMedGoogle Scholar
• 53 Gaydos L A, Freireich E J, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.  N Engl J Med. 1962;  266 905-909
  CrossrefPubMedGoogle Scholar
• 54 Rinder H M, Arbini A A, Snyder E L. Optimal dosing and triggers for prophylactic use of platelet transfusions.  Curr Opin Hematol. 1999;  6 437-441
  CrossrefPubMedGoogle Scholar
• 55 Drews R E. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.  Clin Chest Med. 2003;  24 607-622
  CrossrefPubMedGoogle Scholar
• 56 Triulzi D. Optimizing Platelet Transfusion Therapy. Baltimore, MD: Institute for Transfusion Medicine. 1997
  Google Scholar
• 57 Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation.  Semin Thromb Hemost. 2001;  27 605-617
  Article in Thieme ConnectPubMedGoogle Scholar
• 58 Taylor Jr F B, Chang A, Ruf W et al.. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody.  Circ Shock. 1991;  33 127-134
  PubMedGoogle Scholar
• 59 Creasey A A, Chang A C, Feigen L, Wun T C, Taylor Jr F B, Hinshaw L B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.  J Clin Invest. 1993;  91 2850-2860
  CrossrefPubMedGoogle Scholar
• 60 Taylor F B, Chang A C, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli .  Blood. 1998;  91 1609-1615
  PubMedGoogle Scholar
• 61 Pixley R A, De La Cadena R, Page J D et al.. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: in vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.  J Clin Invest. 1993;  91 61-68
  CrossrefPubMedGoogle Scholar
• 62 van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation.  Semin Thromb Hemost. 2001;  27 639-651
  Article in Thieme ConnectPubMedGoogle Scholar
• 63 Drake T A, Cheng J, Chang A, Taylor Jr F B. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis.  Am J Pathol. 1993;  142 1458-1470
  PubMedGoogle Scholar
• 64 Taylor Jr F B, Chang A C, Peer G T et al.. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage.  Blood. 1991;  78 364-368
  PubMedGoogle Scholar
• 65 Mesters R M, Helterbrand J, Utterback B G et al.. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications.  Crit Care Med. 2000;  28 2209-2216
  PubMedGoogle Scholar
• 66 Yan S B, Helterbrand J D, Hartman D L, Wright T J, Bernard G R. Low levels of protein C are associated with poor outcome in severe sepsis.  Chest. 2001;  120 915-922
  CrossrefPubMedGoogle Scholar
• 67 Yan S B, Dhainaut J F. Activated protein C versus protein C in severe sepsis.  Crit Care Med. 2001;  29(7 Suppl) S69-S74
  PubMedGoogle Scholar
• 68 Cheng T, Liu D, Griffin J H et al.. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.  Nat Med. 2003;  9 338-342
  CrossrefPubMedGoogle Scholar
• 69 Faust S N, Levin M, Harrison O B et al.. Dysfunction of endothelial protein C activation in severe meningococcal sepsis.  N Engl J Med. 2001;  345 408-416
  CrossrefPubMedGoogle Scholar
• 70 Dhainaut J F, Yan S B, Margolis B D et al.. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.  Thromb Haemost. 2003;  90 642-653
  PubMedGoogle Scholar
• 71 Liaw P, Ferrell G, Loeb M, Foley R, Weitz J, Esmon C T. Patients with sepsis vary markedly in their ability to generate activated protein C [abstract].  Blood. 2001;  98 445a
  PubMedGoogle Scholar
• 72 Hermans P W, Hibberd M L, Booy R et al.. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.  Lancet. 1999;  354 556-560
  CrossrefPubMedGoogle Scholar
• 73 Westendorp R G, Hottenga J J, Slagboom P E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock.  Lancet. 1999;  354 561-563
  CrossrefPubMedGoogle Scholar
• 74 Raaphorst J, Johan Groeneveld A B, Bossink A W, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.  Thromb Haemost. 2001;  86 543-549
  PubMedGoogle Scholar
• 75 Tomashefski Jr J F. Pulmonary pathology of the adult respiratory distress syndrome.  Clin Chest Med. 1990;  11 593-619
  PubMedGoogle Scholar
• 76 Hasegawa N, Husari A W, Hart W T, Kandra T G, Raffin T A. Role of the coagulation system in ARDS.  Chest. 1994;  105 268-277
  PubMedGoogle Scholar
• 77 Taylor Jr F B, Toh C H, Hoots W K, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.  Thromb Haemost. 2001;  86 1327-1330
  Article in Thieme ConnectPubMedGoogle Scholar
• 78 Mammen E F. Coagulation abnormalities in liver disease.  Hematol Oncol Clin North Am. 1992;  6 1247-1257
  PubMedGoogle Scholar
• 79 Clarke B J, Sridhara S, Woskowska Z, Blajchman M A. Consumption of plasma factor VII in a rabbit model of nonovert disseminated intravascular coagulation.  Thromb Res. 2002;  108 329-334
  CrossrefPubMedGoogle Scholar
• 80 Feinstein D I. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy.  Blood. 1982;  60 284-287
  PubMedGoogle Scholar
• 81 Dellinger R P, Carlet J M, Masurtt et al.. Surviving sepsis campaign management guidelines committee. Surviving sepsis campaign guidelines for management of severe repsis and saptic shock.  Crit Care Med. 2004;  32 858-873
  CrossrefPubMedGoogle Scholar
• 82 Laterre P F, Heiselman D. Management of patients with severe sepsis, treated by drotrecogin alfa (activated).  Am J Surg. 2002;  184(6A Suppl) S39-S46
  CrossrefPubMedGoogle Scholar
• 83 Aoki N, Matsuda T, Saito H et al.. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation.  Int J Hematol. 2002;  75 540-547
  PubMedGoogle Scholar
• 84 Joyce D, Yan B, Basson B R et al.. Disseminated intravascular coagulation in severe sepsis patients treated with recombinant human activated protein C [abstract].  Blood. 2001;  98 445a
  PubMedGoogle Scholar
• 85 Ely E W, Angus D C, Williams M D, Bates B, Qualy R, Bernard G R. Drotrecogin alfa (activated) treatment of older patients with severe sepsis.  Clin Infect Dis. 2003;  37 187-195
  CrossrefPubMedGoogle Scholar
• 86 Mari D, Mannucci P M, Coppola R, Bottasso B, Bauer K A, Rosenberg R D. Hypercoagulability in centenarians: the paradox of successful aging.  Blood. 1995;  85 3144-3149
  PubMedGoogle Scholar
• 87 Cohen H J, Harris T, Pieper C F. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly.  Am J Med. 2003;  114 180-187
  CrossrefPubMedGoogle Scholar
• 88 Yamamoto K, Shimokawa T, Yi H et al.. Aging accelerates endotoxin-induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging.  Am J Pathol. 2002;  161 1805-1814
  CrossrefPubMedGoogle Scholar

E. Wesley ElyM.D. M.P.H. 

Center for Health Services Research

#6109 MCE, Vanderbilt University Medical Center

Nashville, TN 37232-8300

Email: wes.ely@vanderbilt.edu